Stay updated on Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedRevision v3.5.0 added; revision v3.4.3 removed.SummaryDifference0.1%

- Check14 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check43 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding lapse notice and the older Revision: v3.4.1 entry.SummaryDifference0.4%

- Check50 days agoChange DetectedThe page now displays a government funding lapse notice and the site version was updated to Revision: v3.4.1, which are administrative updates and do not affect core study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check57 days agoChange DetectedShow glossary control added and metadata labels revised (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) replacing the previous QC/Revision label. No core study content, eligibility criteria, or results are affected; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check71 days agoChange DetectedThe page now shows the updated site revision: Revision: v3.3.4, replacing the prior v3.3.3 tag. This is a minor backend update that does not alter study details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.